How many xcur coins are there in the market?
It has a circulating supply of 8,340,487 XCUR coins and a max. supply of 8,500,000 XCUR coins. If you would like to know where to buy Curate, the top cryptocurrency exchanges for trading in Curate stock are currently KuCoin, FMFW.io, Gate.io, PancakeSwap (V2), and Hoo.
What is the commission structure of xcur?
Curate provides a fairer and more transparent open marketplace by offering an industry low 4% seller commission for both marketplaces and provides buyers with zero fees when they use XCUR, curates native token, to purchase in-app. All buyers and sellers are also rewarded in XCUR on all transactions.
Where can I buy curate stock?
If you would like to know where to buy Curate, the top cryptocurrency exchanges for trading in Curate stock are currently KuCoin, FMFW.io, Gate.io, PancakeSwap (V2), and Hoo. You can find others listed on our crypto exchanges page.
Should I buy XCUR stock?
The financial health and growth prospects of XCUR, demonstrate its potential to outperform the market. It currently has a Growth Score of C. Recent price changes and earnings estimate revisions indicate this would be a good stock for momentum investors with a Momentum Score of A.
Will XCUR stock go up?
Stock Price Forecast The 1 analysts offering 12-month price forecasts for Exicure Inc have a median target of 7.50, with a high estimate of 7.50 and a low estimate of 7.50. The median estimate represents a +276.88% increase from the last price of 1.99.
Why did XCUR stock drop?
XCUR reported 2021 net loss of $64.1M vs. net loss of $24.7M in 2020. The wider loss was driven by lower non-cash revenue largely hit by the reversal of non-cash revenue in 2021 associated with the AbbVie collaboration as well as higher R&D and G&A costs.
Is Exicure stock a buy?
Exicure has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Why is OCGN stock down?
Shares of Ocugen (NASDAQ: OCGN) were sinking 4.8% lower as of 11 a.m. ET on Tuesday after falling as much as 7.1% earlier in the day. Instead, today's decline appears to be due to short-term profit-taking after Ocugen jumped late last week after a positive regulatory development in India for COVID-19 vaccine Covaxin.
Should I buy or sell Exicure stock right now?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exicure in the last twelve months. There are currently 1 hold rating and 1...
What is Exicure's stock price forecast for 2022?
2 brokers have issued 1-year target prices for Exicure's shares. Their forecasts range from $2.25 to $6.00. On average, they anticipate Exicure's s...
How has Exicure's stock performed in 2022?
Exicure's stock was trading at $0.2021 on January 1st, 2022. Since then, XCUR stock has decreased by 34.7% and is now trading at $0.1320. View the...
Are investors shorting Exicure?
Exicure saw a decrease in short interest in May. As of May 31st, there was short interest totaling 5,820,000 shares, a decrease of 25.6% from the M...
When is Exicure's next earnings date?
Exicure is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022. View our earnings forecast for Exicure .
How were Exicure's earnings last quarter?
Exicure, Inc. (NASDAQ:XCUR) issued its quarterly earnings data on Monday, May, 16th. The company reported ($0.07) EPS for the quarter. The firm had...
Who are Exicure's key executives?
Exicure's management team includes the following people: Dr. Matthias G. Schroff Ph.D. , CEO, Pres & Director (Age 53, Pay $479.09k) Mr. Brian C...
Who are some of Exicure's key competitors?
Some companies that are related to Exicure include Syros Pharmaceuticals (SYRS) , Mustang Bio (MBIO) , Longboard Pharmaceuticals (LBPH) , SCYNE...
What is Exicure's stock symbol?
Exicure trades on the NASDAQ under the ticker symbol "XCUR."
About Exicure
Exicure (NASDAQ:XCUR) Frequently Asked Questions
Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. Its product pipeline include Cavrotolimod (AST-008) and XCUR-FXN. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in June 2011 and is headquartered in Skokie, IL.
Ideas
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exicure in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Exicure stock. View analyst ratings for Exicure or view top-rated stocks.
Profile
Exicure, Inc., a clinical-stage biotechnology company, develops therapeutics for neurology, immuno-oncology, inflammatory diseases, and genetic disorders based on its proprietary spherical nucleic acid (SNA) technology. Its drug candidate includes cavrotolimod (AST-008) that is in a Phase 1b/2 clinical trials in patients with advanced solid tumors.
Signals & Forecast
Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. Its product pipeline include Cavrotolimod (AST-008) and XCUR-FXN. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in June 2011 and is headquartered in Skokie, IL.
Support, Risk & Stop-loss
A buy signal was issued from a pivot bottom point on Friday, January 28, 2022, and so far it has risen 9.60%. Further rise is indicated until a new top pivot has been found. Some negative signals were issued as well, and these may have some influence on the near short-term development. The Exicure, Inc.
Is Exicure, Inc. stock A Buy?
Exicure, Inc. finds support from accumulated volume at $0.16 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Insiders are positive buying more shares than they are selling in Exicure, Inc
Exicure, Inc. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
Golden Star Signal
In the last 100 trades there were 34.92 million shares bought and 1.35 million shares sold. The last trade was done 64 days ago by Gates Frontier, Llc who sold 1.27 million shares. The large amount of stocks bought compared to stocks sold indicate that the insiders believe there is a potential good upside.
Top Fintech Company
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
